title: Approved Beta interferons in relapsing-remitting multiple sclerosis: is there an odd one out?
abstract: Three interferons are marketed for the treatment of relapsing-remitting multiple sclerosis. In its pivotal trial, one of them demonstrated impressive efficacy as a once-weekly regimen, but later head-to-head studies and reviews questioned its superiority. Analysis of this pivotal trial in publications and health authority reviews has shown that its early termination might have caused attrition bias. Censored patients were different from those completing the study on magnetic resonance imaging parameters and benefited from placebo in terms of relapse rate. Early progression of disability and differences in follow-up duration could have favored the benefit observed for the progression of disability outcome. Only the raw data could be of help to confirm or refute doubts about this trial. Raw data should be made available to the scientific community.
authors: Alexis
authors: A
authors: Clapin
keywords: efficacy; interferons; relapsing-remitting multiple sclerosis
references: Mult Scler. 2005 Dec;11(6):624-5
references: 16320720
references: Ann Neurol. 1998 Jan;43(1):79-87
references: 9450771
references: Lancet. 2003 Feb 15;361(9357):545-52
references: 12598138
references: Trials. 2011 Nov 23;12:249
references: 22112900
references: Ann Neurol. 2002 Apr;51(4):481-90
references: 11921054
references: Neurology. 2002 Nov 26;59(10):1496-506
references: 12451188
references: Ann Neurol. 1999 Aug;46(2):197-206
references: 10443885
references: Neurology. 1995 Jul;45(7):1277-85
references: 7617182
references: Ann Neurol. 1996 Mar;39(3):285-94
references: 8602746
references: Brain. 1991 Apr;114 ( Pt 2):1057-67
references: 2043941
references: Neurology. 1993 Apr;43(4):662-7
references: 8469319
references: Lancet. 2002 Apr 27;359(9316):1453-60
references: 11988242
references: Neurologia. 1998 Apr;13(4):162-5
references: 9608754
references: Neurology. 1993 Apr;43(4):655-61
references: 8469318
references: Neurology. 2002 Jan 22;58(2):169-78
references: 11805241
references: Neurology. 2008 Dec 9;71(24 Suppl 3):S8-13
references: 19064873
references: Trials. 2010 Jan 29;11:9
references: 20113465
references: Lancet. 1998 Nov 7;352(9139):1498-504
references: 9820297
references: Arch Neurol. 1998 Dec;55(12):1578-80
references: 9865805
references: N Engl J Med. 2000 Sep 28;343(13):898-904
references: 11006365
references: Neurology. 1997 Aug;49(2):358-63
references: 9270562